| Bertolet, Barry |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17006 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
| Recruiting | 3 | 14000 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 04/29 | 04/29 | | |
NCT05562934: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. |
|
|
| Active, not recruiting | 2 | 191 | Europe, Japan, US, RoW | Experimental drug, Placebo | Novartis Pharmaceuticals | Resistant Hypertension | 07/24 | 08/24 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
| Active, not recruiting | N/A | 75 | US | Intravascular Lithotripsy | Shockwave Medical, Inc. | Peripheral Arterial Disease | 04/24 | 04/25 | | |
| Recruiting | N/A | 900 | US | Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention | Medtronic Cardiac Rhythm and Heart Failure | Heart Failure NYHA Class II, Heart Failure NYHA Class III | 04/25 | 04/25 | | |
| Recruiting | N/A | 492 | US | Sirolimus Drug Coated Balloon, Plan balloon Angioplasty (POBA) | Concept Medical Inc., Cardiovascular Research Foundation, New York | In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease | 09/25 | 02/28 | | |
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. |
|
|
| Active, not recruiting | N/A | 525 | US | Investigational LUX-Dx ICM Implant | Boston Scientific Corporation | Heart Failure | 05/26 | 06/26 | | |
| Ong, Stephen |
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate |
|
|
| Completed | 4 | 191 | US | Pegloticase with MTX, Methotrexate | Amgen | Chronic Uncontrolled Gout, Gout, Uncontrolled Gout | 01/24 | 03/24 | | |
NCT05026866: A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Recruiting | 3 | 2600 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
NCT05690204: Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. |
|
|
| Recruiting | 2 | 80 | US | SAP001, Xanthine Oxidase Inhibitor, Colchicine | Shanton Pharma Co., Ltd. | Gout | 12/24 | 01/25 | | |
NCT05562934: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. |
|
|
| Active, not recruiting | 2 | 191 | Europe, Japan, US, RoW | Experimental drug, Placebo | Novartis Pharmaceuticals | Resistant Hypertension | 07/24 | 08/24 | | |
| Active, not recruiting | 2 | 175 | Europe, Canada, Japan, US, RoW | LY3561774, Placebo | Eli Lilly and Company | Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia | 03/24 | 06/24 | | |
| Rojas, Yaneicy Gozalez |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Recruiting | 3 | 600 | Japan, US | Remternetug (IV), LY3372993, Remternetug (SC), Placebo | Eli Lilly and Company | Alzheimer's Disease | 10/25 | 10/26 | | |
NCT05026866: A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Recruiting | 3 | 2600 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
| Active, not recruiting | 2/3 | 225 | Canada, US | Piromelatine 20 mg, Neu-P11, Placebo | Neurim Pharmaceuticals Ltd., Syneos Health | Alzheimer's Disease | 06/25 | 06/25 | | |
| Recruiting | 2 | 200 | US | Allopregnanolone, Allo, Placebo | University of Arizona, National Institute on Aging (NIA), Syneos Health, ADM Diagnostics, Inc., University of Southern California | Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases | 04/25 | 12/26 | | |
| Active, not recruiting | N/A | 2000 | US | | University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health | Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia | 04/24 | 04/24 | | |
| Ables, Lilia Rodriguez |
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid |
|
|
| Active, not recruiting | 3 | 580 | US | Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP | Chiesi Farmaceutici S.p.A. | Asthma | 06/24 | 06/24 | | |
NCT05026866: A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Recruiting | 3 | 2600 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
| Ong, Spencer |
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate |
|
|
| Completed | 4 | 191 | US | Pegloticase with MTX, Methotrexate | Amgen | Chronic Uncontrolled Gout, Gout, Uncontrolled Gout | 01/24 | 03/24 | | |
NCT05690204: Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. |
|
|
| Recruiting | 2 | 80 | US | SAP001, Xanthine Oxidase Inhibitor, Colchicine | Shanton Pharma Co., Ltd. | Gout | 12/24 | 01/25 | | |
